Top Clinical Trials companies in Cayman Islands by EBITDA
This ranking features the top 2 Clinical Trials companies in Cayman Islands ranked by EBITDA, totalling a EBITDA of USD -142.08 M, for January 15, 2025.
Cayman Islands
Clinical Trials
EBITDA
# |
Name |
EBITDA |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
USD -40.87 M
|
Dec. 31, 2023 | USD 8.53 | -0.47% |
|
Cayman Islands |
|
| 2 |
USD -101.22 M
|
Dec. 31, 2023 | USD 2.01 | 1.52% |
|
Cayman Islands |
Frequently Asked Questions
-
Which Clinical Trials company in Cayman Islands has the highest EBITDA ?
The Clinical Trials company in Cayman Islands with the highest EBITDA is Theravance Biopharma, Inc. (NasdaqGM: TBPH) at USD -40.87 M.
-
Which Clinical Trials company in Cayman Islands has the lowest EBITDA ?
The Clinical Trials company in Cayman Islands with the lowest EBITDA is Adlai Nortye Ltd. American Depositary Shares (NasdaqGM: ANL) at USD -101.22 M.
-
What are the top 10 Clinical Trials companies in Cayman Islands by EBITDA ?
The top 10 Clinical Trials companies in Cayman Islands by EBITDA are Theravance Biopharma, Inc. and Adlai Nortye Ltd. American Depositary Shares.
-
What are the bottom 10 Clinical Trials companies in Cayman Islands by EBITDA ?
The bottom 10 Clinical Trials companies in Cayman Islands by EBITDA are Adlai Nortye Ltd. American Depositary Shares and Theravance Biopharma, Inc..